Quantcast

Latest Insulin Stories

2014-10-31 08:26:32

Conference Call Scheduled for Monday, November 3, 2014 at 10:00 a.m. Eastern time JERUSALEM, October 31, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to...

2014-10-30 12:29:40

DALLAS, October 30, 2014 /PRNewswire/ -- According to the new market research report "Pen Needles Market by Type (Standard and Safety), by Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, and 12mm), by Therapy (Insulin, Glucagon-like peptide, Growth Hormones) - Analysis & Global Forecast to 2019", published by MarketsandMarkets, analyzes and studies the major market drivers, threats, opportunities, and challenges. This report studies the global Pen Needles Market for the forecast...

2014-10-29 08:34:57

First Ever Person with Type 1 Diabetes Receives Experimental Encapsulated Human Stem Cell-Derived Beta Cell Replacement Therapy NEW YORK, Oct. 29, 2014 /PRNewswire-USNewswire/ -- JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, announced today that JDRF-funded partner, ViaCyte, Inc., a leading regenerative medicine company, has for the first time ever implanted a person with type 1 diabetes (T1D) with an experimental encapsulated cell...

2014-10-29 08:34:38

SAN DIEGO, Oct. 29, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the first patient in its Phase 1/2 study was successfully implanted with VC-01(TM), its embryonic stem cell-derived islet replacement product candidate being developed as a treatment for type 1 diabetes. This Phase 1/2 clinical trial, designed to evaluate the VC-01 product candidate directly in patients with type 1 diabetes, is initially being conducted at UC...

2014-10-29 08:33:30

NovoFine® Plus is the shortest and thinnest pen needle in the Novo Nordisk family of needles designed for diabetes pens PLAINSBORO, N.J., Oct. 29, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its shortest and thinnest pen needle, NovoFine(®) Plus, in the United States. NovoFine(®) Plus is a universal needle that works with all currently available insulin and some GLP-1 receptor agonist pens. The Food and Drug...

2014-10-22 08:32:22

Demonstrates Proof-of-Concept for ORMD-0801 Oral Insulin to Reduce Exogenous Insulin Requirements JERUSALEM, October 22, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1...

2014-10-21 12:32:35

WORCESTER, Mass., Oct. 21, 2014 /PRNewswire/ -- Grove Instruments Inc., a medical device company based in Worcester, MA, developing the world's first noninvasive glucometer today announced that the Company has achieved a landmark clinical milestone known internally as "durable calibration." "This achievement was the last hurdle on the critical path to commercialization of our first product," explained Arthur Combs, Grove's CEO. "We have already identified our initial target markets...

2014-10-21 08:34:10

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Empagliflozin plus metformin is part of the Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) Diabetes alliance portfolio. "Type 2...

2014-10-21 08:33:10

Uppsala University Hospital in Sweden will enroll 8 patients in the study, partially supported by a recent grant by the JDRF ROSH HAAYIN, Israel, October 21, 2014 /PRNewswire/ -- Beta-O2 announced today that the first patient participating in the company's first broad study of the ssAir Bio-Artificial Pancreas has been successfully implanted. ssAir is in development as a treatment and a potential cure for type 1 diabetes (T1D). Approximately 3 million people have T1D in the...

2014-10-20 08:31:51

BRIDGEWATER, N.J., Oct. 20, 2014 /PRNewswire/ -- Valeritas, Inc., a leader in simple, disposable basal-bolus insulin delivery technology designed for patients with Type 2 diabetes, announced today that it has received a 2014 Cardinal Health Supply Chain Excellence Award. The award was presented October 16(th) at Cardinal's annual Business Partners Conference in Columbus, Ohio. The Cardinal Health Supply Chain Excellence Award recipients are judged across a variety of metrics...


Latest Insulin Reference Libraries

Pancreas
2013-01-02 11:22:15

The pancreas is a digestive and an endocrine organ with both endocrine and exocrine functions. It is about six inches long located in the upper portion of the abdominal cavity. The head of the pancreas lies within the indentation of the duodenum and is connected to it by the pancreatic duct. The uncinate process extends from the head and the neck connects to the body of the pancreas, which lies directly behind the stomach. The tail of the pancreas extends to the left side of the body and is...

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (2 articles) »
Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related